RNF180 (Ring finger protein 180) is an integral membrane protein consisting of a RING finger (cysteine/histidine rich (C3HC4) domain for binding E2 enzymes, a basic coiled-coil domain, a novel conserved domain (DSPRC) and a hydrophobic transmembrane region at the C-terminal end. It acts as a novel tumor suppressor gene. It is expressed in the developing and mature brain including kidney, testis, and uterus.
Synonyms: Anti-RING finger protein 180
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: RNF180 (Ring finger protein 180) is a membrane-bound E3 ubiquitin ligase involved in the ubiquitin ligase activity. During protein ubiquitination pathway, it binds to and degrades the protein at the cytoplasmic side of the endoplasmic reticulum. RNF180 has been reported as a prognosis marker of gastric cancer.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC